| 1 |
Appointment of the following non-exective directors, each for a term of three (3) years, ending at the close of the Annual General Meeting of 2029 |
|
| 1a |
Paul Auvil |
✓ For(28.911)
|
| 1b |
Alison Gleeson |
✓ For(28.911)
|
| 1c |
Julia Liuson |
✓ For(28.911)
|
| 2 |
Adoption of Dutch Statutory Annual Accounts for fiscal year 2026 |
✓ For(28.911)
|
| 3 |
Appointment of PricewaterhouseCoopers Accountants N.V. as the external auditor of the Company's Dutch Satutory Annual Accounts for fiscal year 2027 |
✓ For(28.911)
|
| 4 |
Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for fiscal year 2027 |
✓ For(28.911)
|
| 5 |
Grant of full discharge to the Company's executive directors from liability with respect to the performance of their duties during fiscal year 2026 |
✓ For(28.911)
|
| 6 |
Grant of full discharge to the Company's non-executive directors from liability with respect to the performance of their duties during fiscal year 2026 |
✓ For(28.911)
|
| 7 |
Authorization of the Board of Directors to issue ordinary shares and grant rights to acquire ordinary shares |
✓ For(28.911)
|
| 8 |
Authorization of the Board of Directors to restrict or exclude pre-emptive rights for issuances of ordinary shares and grants of rights |
✓ For(28.911)
|
| 9 |
Authorization of the Board of Directors to repurchase ordinary shares in the capital of the Company |
✓ For(28.911)
|
| 10 |
Non-binding advisory vote to approve the compensation of the Company's named executive officers as described in the proxy statement |
✓ For(28.911)
|
| 11 |
Non-binding advisory vote to approve the frequency of future non-binding advisory votes to approve the compensation of our named executive officers. |
1 Year
|